Therefore, in a case–control study nested in the NHS, we examined the association between circulating prolactin levels measured 10 or fewer years prior to diagnosis and risk of breast cancer by tumor expression of the PRLR, pSTAT5, and phosphorylated JAK2 (pJAK2). This evidence concerns the gene JAK2 and neoplasm.